The positive experience with 225Ac- and 213Bi-labeled small molecules for targeting the prostate-specific membrane antigen (PSMA), as well as the introduction of 223RaCl2 (XofigoTM) for the treatment of prostate cancer-related bone metastases, have escalated the concept of α-therapy. Here, FOLH1 is linked to prostate cancer.